HDAC6 and neoplasm: Utilizing Arid1a-mutated OCCC mice treated with the HDAC6 inhibitor and anti-PD-L1 immune checkpoint blockade, they further found that tumor burden reduced and mice survival improved because of the activation and increased presence of interferon-gamma-positive CD8 T cells.